Dublin, March 25, 2019 (GLOBE NEWSWIRE) -- The "Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025
The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.
Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come.
Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.
Further key findings from the study suggest:
- Diabetes segment led the market in 2017, in terms of revenue generation,owing to higher prevalence and drug usage
- Obesity segment is expected to register a CAGR of 9.27% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes
- Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases
- The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis
- Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position
- Oral route of administration was the key revenue-generating segment in 2017owing to its benefits, such as high reliability and ease of administration
- North America was the largest regional market in 2017 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesity
Key Topics Covered:
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of metabolic disorders
3.1.1.2 Collaborations between manufacturers and research facilities
3.1.1.3 Government initiatives
3.1.2 Market restraint analysis
3.1.2.1 Expensive rare disease therapies
3.1.2.2 Ambiguous regulatory policies
3.2 Penetration & growth prospect mapping
3.3 Metabolic Disorder Therapeutics - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter's
Chapter 4 Metabolic Disorder Therapeutics Market: Disease Estimates & Trend Analysis
4.1 Metabolic Disorder Therapeutics Market by Disease, Movement Analysis
4.2 Lysosomal Storage Diseases
4.2.1 Lysosomal storage diseases market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.2 Gaucher's Disease
4.2.3 Metachromatic leukodystrophy
4.2.4 Hurler - Scheie Disease
4.2.5 Sanfilipo A disease
4.2.6 Other diseases
4.3 Diabetes
4.4 Obesity
4.5 Inherited Metabolic Disorders
4.6 Hypercholesterolemia
Chapter 5 Metabolic Disorder Therapeutics Market: Therapy Type Estimates & Trend Analysis
5.1 Metabolic Disorder Therapeutics Market: Therapy Type Movement Analysis
5.2 Enzyme Replacement Therapy
5.3 Cellular Transplantation
5.4 Small Molecule-Based Therapy
5.5 Substrate Reduction Therapy
5.6 Gene Therapy
5.7 Drug Therapy
Chapter 6 Metabolic Disorder Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1 Metabolic Disorder Therapeutics market: route of administration movement analysis
6.2 Oral Administration
6.3 Parenteral Administration
6.4 Other route of administration
Chapter 7 Metabolic Disorder Therapeutics Market: Regional Outlook
7.1 Metabolic Disorder Therapeutics market share by region, 2017 & 2025 (USD Billion)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
- Novo Nordisk
- Eli Lilly and Company
- Shire Plc
- Sanofi
- Merck KgaA
- AstraZeneca
- AbbVie Inc.
- Actelion Pharmaceuticals Ltd
- Amgen Inc.
- Biocon
- BioMarin
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cipla Inc.
- CymaBay Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/qwgvlt/global_88_93_bn?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.